Neovacs is a French biotechnology company developing the next generation of therapeutic vaccines for autoimmune and inflammatory diseases and certain types of cancers. Founded in 1993 by the famous French immunologist Daniel Zagury, MD,Ph.D, our company is a spin-off from the University Pierre et Marie Curie in Paris, located in Paris with 20 staff. Our Mission Our ambition is to become a major player in the treatment of chronic autoimmune and inflammatory and certain types of cancers. Using the Kinoid technology, we develop therapeutic vaccines targeting specific cytokines involved in the pathogenesis of these diseases. Our goal is to advance research and provide new treatments that address patient needs and provide a superior quality of life while participating in the reduction of healthcare costs. Our strategy To manage risk and accelerate time-to-market, Neovacs has chosen to focus on validated or well-established targets with considerable unmet medical need. As of today, our clinical efforts are focused on the development of IFNα-Kinoid, an anti interferon alpha currently developed for the treatment of Systemic Lupus Erythematosus (SLE) or lupus Our Kinoid technology targets major medical and commercial opportunities, with potential to reach still broader therapeutic areas since the Kinoid technology can be applied to any cytokine target.
Type
Public
HQ
Paris, FR
Founded
1993
Employees
19 (est)
Neovacs was founded in 1993 and is headquartered in Paris, FR

Neovacs Locations

Paris, FR

Neovacs Metrics

Neovacs Summary

Market capitalization

€32 M

Closing share price

€0.72
Neovacs's latest market capitalization is €32 M.

Neovacs Market Value History

Neovacs Company Life